Banking & Finance  November 18, 2026

VitriVax raises $87M Series C to advance Lyme disease vaccine

VitriVax has closed an $87 million Series C, capital that it plans to use to advance its leading Lyme disease vaccine candidate and expand its drug-discovery pipeline.

Lucas is an award-winning journalist who worked at news agencies from Maryland to Wyoming to South Carolina before putting roots down in Colorado.

Related Posts

Sign up for BizWest Daily Alerts
Closing in 8 seconds...